Docetaxel Suppliers & Bulk Manufacturers
Available Forms: injection
Available Strengths: 20 mg/1 mL, 80 mg/4 mL,160 mg/8 mL
Reference Brands: Taxotere®.
Category:
Oncology Cancer Care
Docetaxel is an intravenous chemotherapy drug used to treat cancers like breast cancer, NSCLC, prostate cancer, and more. Available in 20 mg/mL, 80 mg/4 mL, and 160 mg/8 mL vials, it is marketed as Taxotere® in both the US and EU, providing key B2B opportunities in oncology.
Docetaxel is available in injection
and strengths such as 20 mg/1 mL, 80 mg/4 mL,160 mg/8 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Docetaxel is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Docetaxel can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Docetaxel is an intravenous chemotherapy agent used to treat a variety of cancers, including breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, and head and neck cancers. As a taxane, it works by inhibiting cell division, effectively preventing cancer cell proliferation. Available in 20 mg/mL, 80 mg/4 mL, and 160 mg/8 mL vial strengths, Docetaxel is marketed under the brand name Taxotere® in both the US and EU. The drug offers significant B2B opportunities for pharmaceutical companies targeting oncology treatments in these regions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing